castration-resistant prostate cancer

Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark

This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

.

Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark

A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

.

Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate Cancer Bookmark

Excerpt:

“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.

“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”

Go to full article published by Healio on Feb 14, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

The Link Between Apalutamide and QOL in Non-Metastatic CRPC Bookmark

Excerpt:

“Adding apalutamide to androgen deprivation therapy (ADT) does not appear to harm health-related quality of life (HRQOL) in men with nonmetastatic castration-resistant prostate cancer (CRPC), according to new research published in Lancet Oncology.

“Previous research has showed that men in this patient population who received apalutamide had longer metastasis-free survival and a longer time to symptomatic progression compared with those who received placebo. This new study found that adding apalutamide still preserves HRQOL. Specifically, the group mean patient-reported outcome scores over time demonstrated HRQOL was maintained from baseline (initiation of apalutamide), and it was similar over time among men receiving apalutamide versus placebo.”

Go to full article published by Cancer Network on Oct 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Combo Tx No Help After PSA Progression in mCRPC Bookmark

Excerpt from MedPage Today:

“Adding abiraterone acetate (Zytiga) to enzalutamide (Xtandi) did not improve progression-free survival (PFS) after prostate-specific antigen (PSA) progression in men on enzalutamide monotherapy for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), researchers found.

“In the randomized, double-blind PLATO trial, the median PFS in patients treated with enzalutamide plus abiraterone and prednisone was 5.7 months. By comparison, the PFS was 5.6 months in the control group treated with abiraterone and prednisone plus placebo (hazard ratio [HR] 0.83; P=0.22).”

Go to full article published by MedPage Today on July 28, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Abiraterone May Be More Effective in Black Men With Prostate Cancer Bookmark

Excerpt:

“Black men with metastatic castration-resistant prostate cancer (CRPC) who received hormonal therapy with the adrenal inhibitor abiraterone had greater and longer-lasting responses compared with white men, according to the results of a late-breaking study (abstract LBA5009) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago June 1–5.

“The prospective study found that black men were more likely to have a decline in prostate-specific antigen (PSA) and had a longer median time to PSA worsening than white men. The findings were presented by Daniel George, MD, professor of medicine and surgery at Duke University.”

Go to full article published by Cancer Network on Jun 2, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.